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Tropheryma whipplei is the etiologic pathogenic agent 
of Whipple disease (WD), characterized by various clinical 
signs, such as diarrhea, weight loss, lymphadenopathy, and 
polyarthritis. PCR-based methods for diagnosis of WD have 
been developed. T. whipplei has been identiﬁ  ed in saliva 
and stool samples from patients with WD and from healthy 
persons. T. whipplei DNA has also been found in bronchoal-
veolar lavage (BAL) samples of a child with pneumonia. We 
detected DNA of T. whipplei in 6 (3%) of 210 BAL samples 
collected in intensive care units by using 16S rDNA and 
speciﬁ  c quantitative PCR. We identiﬁ  ed 4 novel genotypes 
of T. whipplei. In 1 case, T. whipplei was the only bacterium; 
in 4 others, it was associated with buccal ﬂ  ora. We suggest 
that T. whipplei should be investigated as an etiologic agent 
of pneumonia.
T
ropheryma whipplei is a bacterium widely known to be 
associated with Whipple disease (WD), which is char-
acterized by various clinical signs such as diarrhea, weight 
loss, lymphadenopathy, and polyarthritis (1). Furthermore, 
clinical features such as blood culture–negative endocardi-
tis and neurologic lesions have been reported (2). Until 
1991, WD diagnosis was based essentially on histopatho-
logic observations, characterized by positive periodic acid-
Schiff stained inclusions within intestinal macrophages (3) 
and electron microscopy, which has shown the microbio-
logic etiology of the illness (4).
The ﬁ  rst molecular identiﬁ  cation was made by Wil-
son et al. in 1991 (the bacterium was uncultured at that 
time) by using broad-range primers targeting the 16S sub-
unit of rDNA extracted from infected duodenal tissue of 
a patient with WD (5). The bacteria were thus classiﬁ  ed 
within the family Actinomycetes (classiﬁ  cation was based 
on 16S rDNA sequence analysis), and the name Troph-
eryma whippelii was proposed (5,6); the bacterium was 
later modiﬁ  ed to Tropheryma whipplei by La Scola et al. 
(7). Investigators then developed several molecular PCR-
based methods for the diagnosis of WD. Most of these 
methods use probes or primer sets targeting parts of the 
16S or 23S rDNA genes (8).
Successful cultivation of the bacterium by Raoult et 
al. (9) has enabled the adoption of novel diagnostic tools, 
such as immunohistochemistry and serologic tests (10–12). 
Three years after successful cultivation, the genomes of 
2 T. whipplei strains (T–W08/17, GenBank accession no. 
NC004551, and Twist, GenBank accession no. NC004572) 
have been fully sequenced (13,14). Completion of the se-
quencing of these 2 genomes has enabled the design of 
highly speciﬁ  c and sensitive primer pairs that target repeat-
ed DNA sequences unique to the T. whipplei genome (15).
These major advances have enabled the identiﬁ  cation 
of T. whipplei DNA in various specimens such as saliva 
and stools from patients with WD, as well as from asymp-
tomatic carriers, which suggests that the localization of the 
bacterium is not restricted to the digestive tract and that 
other organs might be affected (2,16–18). More recently, 
detection of DNA from T. whipplei in bronchoalveolar la-
vage (BAL) samples from a patient with pneumonia sug-
gests that the bacterium might be involved in respiratory 
diseases (19). We show that T. whipplei could be a poten-
tial infectious agent for patients admitted to intensive care 
units (ICUs) and that it can be found in the BAL samples 
of patients in ICUs.
Materials and Methods
All case-patients (hereafter patients) were admitted to 
1 of 3 ICUs in Marseille, France (1 medical ICU and 2 
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medicosurgical ICUs) during February 2007 through Jan-
uary 2008. Ages ranged from 18 to 94 years. A total of 
210 bronchoalveolar lavage (BAL) ﬂ  uid samples and 197 
blood samples, representing 197 episodes of suspected or 
conﬁ  rmed pneumonia, were collected from 134 patients 
admitted to the 3 ICUs to perform an exhaustive etiologic 
diagnosis of pneumonia. Bronchoalveolar lavage and blood 
sampling were collected as previously described (20) in the 
3 ICUs. The samples were then transported at room temper-
ature to the microbiology laboratory of Timone Hospital, 
Marseille, France, and preserved at –20°C until handling. 
Ventilator-associated pneumonia, community-acquired 
pneumonia, and aspiration pneumonia were deﬁ  ned as pre-
viously described (21–23).
DNA was extracted in a MagnaPure LC workstation 
(Roche Diagnostics, Meylan, France) by using the MagNa 
Pure LC DNA Isolation Kit II (Roche Diagnostics). Pel-
lets from BAL ﬂ  uid samples were mixed with 200 μL of 
lysis buffer and 50 μL of proteinase K, incubated over-
night at 56°C, disrupted for 1 min with glass beads in a 
MagNa Lyser (Roche Diagnostics), and then processed 
on the Magnapure LC workstation by the manufacturer’s 
recommendations. When a BAL sample was cell-poor, to 
concentrate the bacterial cells, we centrifuged 500 μL of 
BAL sample for 15 min at maximum speed, discarded 400 
μL of the supernatant, then resuspended the pellet in the 
remaining 100 μL; the extraction procedure was contin-
ued as described above.
Standard PCR was performed by using the eu-
bacterial broad-range 16S rDNA primer set 536F: 5′-
CAGCAGCCGCGGTAATAC-3′ and rp2: 5′-ACGGC
TACCTTGTTACGACTT-3′ (Eurogentec, Seraing, Bel-
gium). PCR was performed in an ABI Themocycler (Ap-
plied Biosystems, Courtaboeuf, France).The ampliﬁ  ca-
tion was done in a 50-μL ﬁ  nal volume containing 5 μL 
extracted DNA, 1X PCR buffer (5 μL), 2 μL of 25 mM 
MgCl2, 200 μM of each dNTP, 0.2 mM of each 536F and 
rp2 primer, and 1 unit of HotStar Taq DNA Polymerase 
(QIAGEN, Courtaboeuf, France). Ampliﬁ  cation  started 
with an initial incubation at 95°C for 15 min to denature 
DNA and activate polymerase enzymes, followed by 35 
cycles of heating at 95°C for 1 min, annealing at 62°C for 
30 s, and extension at 72°C for 90 s. Ampliﬁ  cation ended 
with an extension step at 72°C for 10 min. The PCR prod-
ucts were puriﬁ  ed by using the Nucleo-Fast 96 PCR Kit 
(MACHEREY-NAGEL, Hoerdt, France) as deﬁ  ned by the 
supplier, and 4 μL of puriﬁ  ed PCR product was sequenced 
in 20 μL ﬁ  nal volume containing sequencing buffer, 3.2 
pmole of forward (536F) or reverse (rp2) primer, 3 μL of 
Big Dye Terminator V1.1 mix (Applied Biosystems), and 8 
μL of deionized water. Sequencing reactions were puriﬁ  ed 
by using Sephadex Gel-Filtration (Sigma-Aldrich Chimie, 
Saint Quentin Fallavier, France), and the puriﬁ  ed products 
were sequenced on an ABI PRISM 3130xl genetic analyzer 
(Applied Biosystems). Sequences obtained were analyzed 
with Autoassembler software and compared with those 
available in the GenBank database by using the BLAST 
program (www.ncbi.nlm.nih.gov/BLAST).
When the BAL ﬂ  uid was polymicrobial, puriﬁ  ed PCR 
products were cloned into PCR II TA cloning vector (Invit-
rogen, Cergy Pontoise, France) by using 3 μL of puriﬁ  ed 
PCR products from the previous step as recommended by 
the manufacturer, and 56–64 white colonies were screened 
for each specimen. The cloned inserts were ampliﬁ  ed with 
M13 primers set (M13F: 5′-GTAAAACGACGGCCAG-3′, 
M13R: 5′-CAGGAAACAGCTATGAC-3′) and sequenced 
as described above.
Quantitative real-time PCR was performed as de-
scribed by the manufacturer by using a LightCycler instru-
ment (Roche Diagnostics) with the QuantiTect Probe PCR 
Kit. First, specimens were tested by using the Twhi3F: 
5′-TTGTGTATTTGGTATTAGATGAAACAG-3′ and 
Twhi3R: 5′-CCCTACAATATGAAACAGCCTTTG-3′ 
primer pair and the speciﬁ   c TaqMan probe Twhi3: 
6-FAM-GGGATAGAGCAGGAGGTGTCTGTCTGG-
TAMRA. When the specimen was positive in this as-
say, the result was conﬁ   rmed by a second quantita-
tive PCR by using the Twhi2F: 5′-TGAGGATGTA
TCTGTGTATGGGACA-3′ and Twhi2R: 5′-TCCTGT
TACAAGCAGTACAAAACAAA-3′ primer set and the 
Twhi2 probe: 6-FAM-GAGAGATGGGGTGCAGGACA
GGG-TAMRA.
Genotyping of T. whipplei detected in the BAL ﬂ  uid 
samples was conducted as described previously (24). Each 
of the 4 highly variable genomic sequences (HVGSs) ob-
tained from each specimen was compared with those avail-
able in the GenBank database and our internal laboratory 
database to determine their corresponding genotype. The 
combination of the 4 HVGSs was then analyzed to deﬁ  ne 
the genotype of the bacteria.
Serologic assays were performed by Western blot-
ting. The T. whipplei Twist strain was cultivated in axenic 
medium as previously reported (25). Native and deglyco-
sylated samples obtained from the total bacterial extract 
were prepared for sodium dodecyl sulfate–polycrylamide 
gel electrophoresis. The assay was performed to test all im-
munoglobulins (Ig), total (IgT), including IgG, IgM, and 
IgA heavy and light chains, as well as to test IgG, IgM, 
and IgA separately, as previously described (26). Detection 
was performed by using chemiluminescence (ECL Western 
Blotting Analysis System) and an automated ﬁ  lm processor 
(Hyperprocessor, GE Healthcare, Buckinghamshire, UK). 
To quantify Western blot bands, we scanned ﬁ  lms with an 
Image Scanner III (GE Healthcare). We performed image 
analysis by using GelEval 1.21b FrogDance software and 
ImageJ software (http://rsb.info.nih.gov/ij).
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Results
Bacterial DNA of T. whipplei was detected in 6 of 
210 BAL ﬂ  uid samples by standard or quantitative PCR 
(Table 1). The patients’ ages ranged from 39 to 73 years 
(mean ± SD 56.83 ± 14.01 years), and all were men (Table 
2). One of those 6 specimens (no. 5) was positive for the 
bacterium in both standard and quantitative PCR assays. 
For this patient, PCR with broad-range primers showed that 
T. whipplei was the only bacterium identiﬁ  ed. Moreover, 
both quantitative PCR assays showed a high level of the 
bacterium in this specimen (cycle threshold = 20 with Whi3 
probe and cycle threshold = 21 with Whi2 probe; 5.105 
copy [Table 1]). This patient was immunocompromised 
and had community-acquired pneumonia and septic shock 
(Table 2). He was admitted to the medical ICU for septic 
shock and acute respiratory distress syndrome complicat-
ing community-acquired pneumonia (Figure). He received 
chemotherapy for difﬁ  cult-to-treat mediastinal lymphoma. 
A lobectomy on his upper right lung had been done 1 year 
before admission for the lymphoma. Lung inﬁ  ltrates were 
present when he was admitted to the hospital. The patient 
was febrile (39.2°C) and hypoxemic (partial pressure of 
oxygen in arterial blood [PaO2] 120 mm Hg for a fraction 
of inspired oxygen [FiO2] at 1), and pancytopenia was evi-
dent after initial examination. He received blood products 
during his ICU stay (9 packed erythrocytes, 4 fresh frozen 
plasma, 3 platelet transfusions). He was empirically treated 
by using ticarcillin/clavulanic acid and erythromycin. He-
modynamic status improved rapidly, and administration of 
vasopressors was stopped by day 2. The patient was ﬁ  nally 
extubated at day 7 and discharged from the ICU on day 10. 
He fully recovered after completing a treatment regimen of 
imipenem, amikacin, and vancomycin.
Specimens nos. 10, 82, 86, 183, and 209 from 5 other 
patients were positive for T. whipplei in quantitative real-
time PCR by using the Twhi3 probe and primer pairs and 
successfully conﬁ   rmed by using the Twhi2 probe and 
primer pairs (Table 1). The bacterial load in each specimen 
is shown in Table 1. Standard cultures were negative; 104 
CFUs were used as the cutoff. The 16S rDNA assay yield-
ed 50 bacteria representing 46 species (Table 1). Of these 
46 bacterial species, 15 had <97% 16S rRNA sequence 
identity with the sequences available in the GenBank da-
tabase, which suggests a potentially new bacterial species 
(Table 1). However, despite the high number of the clones 
screened for these patients, this approach was unable to de-
tect DNA of T. whipplei. This result could be explained 
by the polymicrobial aspect of these specimens caused by 
the presence of oral bacterial ﬂ  ora, which was proven by 
the high number of bacteria identiﬁ  ed from each specimen 
(Table 1). Patients 10, 82, 86, and 183 had a typical buc-
cal ﬂ  ora. Two of these 4 patients had aspiration pneumo-
nia; the remaining 2 had ventilator-associated pneumonia. 
The patient from whom specimen no. 209 was collected 
had ﬂ  ora of an apparent environment and water origin, but 
aspiration pneumonia likely developed.
Genotyping of T. whipplei was successfully performed 
for 4 specimens (specimen nos. 5, 10, 82, and 86). Three 
new T. whipplei genotypes were identiﬁ  ed in specimen nos. 
5, 82, and 86. T. whipplei genotype 3 was isolated from 
specimen 10; this genotype is currently identiﬁ  ed in pa-
tients with endocarditis caused by T. whipplei and in pa-
tients with digestive WD (24). Another new genotype of T. 
whipplei was identiﬁ  ed in specimen no. 183. In this sample, 
because of the low level of the bacterium, only 2 HVGSs 
(HVGS1 and HVGS3) were successfully ampliﬁ  ed. How-
ever, after analysis of the HVGS1 sequence, we concluded 
that it was a new genotype different from those previously 
identiﬁ  ed. Serologic assays showed no immunoreactivity 
in the serum of patients whose BAL samples were positive 
for T. whipplei in molecular assays.
Discussion
We report the use of broad-range primer-based PCR 
amplifying the 16S rDNA gene followed by cloning and 
sequencing to identify bacteria associated with pneumonia 
occurring in mechanically ventilated ICU patients. These 
results agree with previously published studies (19,27,28) 
of cystic ﬁ  brosis patients, which showed that unusual mi-
crobiologic agents can be responsible for pneumonia. The 
present study shows that these unusual agents of pneumo-
nia can also be identiﬁ  ed in mechanically ventilated ICU 
patients. 
Our results show that T. whipplei is an etiologic patho-
gen in pneumonia. We tested samples from all patients 
positive for T. whipplei twice by RTq PCR using differ-
ent primer pairs and probes. In the broad-range PCR-based 
assay, samples from the ﬁ  rst patient were positive for T. 
whipplei by direct ampliﬁ  cation and sequencing of the 16S 
rDNA gene. Together with the published work of Harris et 
al., this positive result prompted us to test systematically 
for T. whipplei in all BAL samples collected (19). Indeed, 
as we were conducting our study, Harris et al. reported 
the detection of T. whipplei in the sputum of a child with 
pneumonia (19). Moreover, we were able to genotype T. 
whipplei in 5 specimens (i.e., 4 further ampliﬁ  cations for 
nos. 5, 10, 82, and 86 and 2 other ampliﬁ  cations for no. 
183). Serologic assays showed no immunoreactivity in the 
serum of the patients of interest. In this age group (61 ± 
3.6 years), the percentage of positivity by Western blot is 
45% (F. Fenollar, D. Raoult, unpub. data). The absence of 
immunoreactivity in serum of patients whose BAL ﬂ  uid 
was positive for T. whipplei in molecular assays shows that 
T. whipplei was probably not present in those patients be-
fore the current pneumonia developed. Moreover, antibody 
response against T. whipplei is paradoxal. We recently 
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Table 1. PCR test results of bronchoalveolar lavage specimens that were positive for Tropheryma whipplei DNA, collected from 6 
intensive care unit patients in Marseille, France, February 2007–January 2008* 
qPCR probe  Other bacteria identified (16S rDNA primer set)  Specimen
no.
16S rDNA 
for T. whipplei Twhi3  Ct Twhi2 Ct Load (copy)  Bacterium Identity, % 
5 + + 20 + 21 5.10
5 – 99
10 – + 30 + 31 4,8.10
2 Streptococcus pneumoniae 99
Actinobacillus pleuropneumoniae 99
Peptostreptococcus sp. 99
82 – + 29 + 28 5,3.10
3 Streptococcus genomosp. C4 99
Uncultured 99
Streptococcus sp. clone 2.17 89
Streptococcus sanguinis  99
Gemella sanguinis  99
Leptotrichia sp.  95
Haemophilus quentini 99
Uncultured Haemophilus sp. 99
Peptostreptococcus sp.  99
Granulicatella para-adiacens  95
Prevotella sp. 99
Prevotella melaninogenica  99
Cloacibacterium normanense  93
Ralstonia solanacearum  99
Haemophilus haemolyticus  99
Uncultured Arcobacter sp. clone DS126 99
Prevotella salivae  99
Streptococcus parasanguis  99
86 – + 31 + 29 7,6.10
2 Uncultured Porphyromonas sp. clone 302E06 99
Uncultured Capnocytophaga sp.  95
Gemella sanguinis 99
Streptococcus constellatus 99
Prevotella melaninogenica 91
Uncultured Porphyromonas sp.  93
Haemophilus parainfluenzae 99
Uncultured Tannerella sp.  98
Prevotella melaninogenica 99
Granulicatella para-adiacens 99
183 – + 36 + 37 50 Staphylococcus epidermidis  99
Porphyromonas gingivalis 99
Pseudomonas sp. 92
Eubacterium sp. 94
Streptococcus anginosus  99
Uncultured Neisseria sp. clone 502G08 99
Treponema sp. 97
Clostridium sp. 97
Acidovorax sp./Diaphorobacter sp. 99
Eubacterium brachy  99
Gemella haemolysans  99
Mycoplasma orale  95
Comamonas denitrificans  95
Prevotella tannerae  98
Peptostreptococcus micros  99
209 – + 35 + 35 70 Abiotrophia defectiva  99
Acidobacteria sp. 94
Afipia genosp. 12 97
Sphingomonas sp. 98
Pseudomonas stutzeri  100
*qPCR, quantitative PCR; Ct, cycle threshold. RESEARCH
showed that patients with chronic asymptomatic carriage 
of T. whipplei in fecal specimens had antibodies to T. whip-
plei; patients with WD did not exhibit or exhibited a low 
reaction to T. whipplei (29). The lack of antibodies for T. 
whipplei in patients points to a recent infection in nonim-
mune persons. 
The pathogenic role played by T. whipplei in pneu-
monia is difﬁ  cult to deﬁ  ne. In the ﬁ  rst patient (specimen 
no. 5), the role of T. whipplei in pneumonia is probable. In 
fact, it was the only pathogen we detected using the broad-
range PCR-based assay, and it was present at a high level 
in an immunocompromised patient (5.105 copies of the 
genome) (Table 1). This patient had community-acquired 
pneumonia when admitted to the hospital. Results for the 5 
other case-patients should be interpreted more cautiously. 
For the patients from whom specimens no. 10, 82, 86, and 
183 were collected, ampliﬁ  cation of the 16S rDNA gene 
showed the presence of several other bacteria usually found 
in oral ﬂ  ora. For the patients from whom specimens 10 and 
82 were collected, both of whom had aspiration pneumo-
nia, we hypothesize that T. whipplei was part of the oral 
or digestive ﬂ  ora that contaminated this patient with many 
other pathogens. It is likely that this was also true for the 
patients from whom specimens 86 and 183 were collected, 
both of whom had ventilator-associated pneumonia. For 
the remaining patient (specimen no. 209), the situation was 
more complex. In fact, we found oral and dental bacteria, 
3 water bacteria, and Pseudomonas stutzeri, which is an 
environmental bacterium. The role of T. whipplei in this 
patient remained unclear.
In summary, we reported a series of patients in whom 
T. whipplei DNA was found in BAL ﬂ  uids. In 1 patient 
(specimen no. 5), the role of T. whipplei in pneumonia is 
highly convincing. For the 5 other cases, T. whipplei was 
identiﬁ  ed, as were other oral and dental bacteria. The patho-
genic role played by T. whipplei in the pneumonia for these 
5 patients in conjunction with other bacteria is difﬁ  cult to 
deﬁ  ne but cannot be excluded. Our ﬁ  ndings conﬁ  rm those 
reported by Harris et al. (19), who found T. whipplei DNA 
in the sputum of a child with pneumonia. The role of T. 
whipplei in ICUs remains to be elucidated. T. whipplei is an 
ubiquitous bacterium in the digestive tract, and it has been 
shown that T. whipplei might be present in the saliva of 
asymptomatic persons (2,30). It is therefore probable that 
T. whipplei could contribute to the occurrence of aspiration 
pneumonia along with bacteria present in the oral ﬂ  ora. The 
presence of T. whipplei as the unique identiﬁ  ed agent in 
one of the reported cases is suggestive of a real pathogenic-
ity of this agent. 
It is too early to conclude whether T. whipplei is an 
etiologic agent of aspiration or isolated pneumonia. Never-
theless, the existence of T. whipplei DNA in ≈3% of BAL 
ﬂ  uid samples collected from patients with pneumonia un-
doubtedly raises questions about its role in the genesis of 
pneumonia that develops in ICU patients.
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Table 2. Demographic and clinical data on 6 intensive care unit patients with pneumonia from whom bronchoalveolar lavage samples
positive for Tropheryma whipplei DNA were collected, Marseille, France, February 2007–January 2008* 
Specimen
no.
Patient
age, y/sex  Immunocompromised  Diagnosis
Type of 
pneumonia
Duration
of MV, d 
Duration of 
ICU stay, d 
T. whipplei
genotype  Outcome
5 39/M Yes (chemotherapy)  Septic shock  CAP 7 10 New  Survived
10 46/M Yes (splenectomy)  Coma Aspiration 3 5 3 Survived
82 65/M No Coma Aspiration 16 27 New  Survived
86 74/M No Pulmonary 
embolism
VAP 42 42 New  Died
183 43/M No Pancreatitis VAP 14 16 New  Survived
209 74/M Yes (corticosteroids)  Spinal cord injury  Aspiration 81 81 ND Died
*MV, mechanical ventilation; ICU, intensive care unit; CAP, community-acquired pneumonia; VAP, ventilator-associated pneumonia; ND, not determined. 
†Based on 4 highly variable genomic sequences. 
Figure. Chest radiograph of patient no. 5, who had community-
acquired pneumonia associated with Tropheryma whipplei.Tropheryma whipplei and Pneumonia
IRD UMR 6236, Medical Faculty, Marseille, France. His main 
research interest is the research of novel pathogenic agents associ-
ated with nosocomial pneumonia.
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